Enter your email address
Submit
Write your message
Volume 9, Issue 1 (Iranian Quarterly Journal of Breast Diseases 2016)
ijbd 2016, 9(1): 7-13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahmanian M, Naghib M, Seyfoori A, Zare A A, Majidzadeh-A K. Investigation of Inhibitory Effect of β-tricalcium Phosphate on MCF-7 Proliferation. ijbd 2016; 9 (1) :7-13
URL: http://ijbd.ir/article-1-503-en.html
URL: http://ijbd.ir/article-1-503-en.html
1- , Naghib@iust.ac.ir
Abstract: (8017 Views)
Introduction: Calcium phosphate nanoparticles such as nano hydroxyapatite have shown excellent physical, chemical and biological properties and have allocated special place in regenerative medicine applications. Recently, the inhibitory effect of hydroxyapatite, as a calcium phosphate, on many cancers has been reported.
Methods: In this article β-tricalcium phosphate was synthesized using co-precipitation method and its physicochemical properties were studied (SEM, FTIR and XRD). Inhibitory effect of beta-tricalcium phosphate nanoparticles on the growth and proliferation of breast cancer cell line MCF-7 was investigated.
Results: In vitro MTT assay studies showed that the inhibitory effect was dependent on the concentration of tricalcium phosphate nanoparticles. In addition, the results demonstrated that the inhibitory effect was 78% attributed to 50 mg. L-1 concentration of tricalcium phosphate nanoparticles.
Conclusion: In lowest concentrations, the inhibitory effect of tricalcium phosphate nanoparticles was higher than others.
Type of Study: Research |
Subject:
Breast Diseases
Received: 2016/06/25 | Accepted: 2016/06/25 | Published: 2016/06/25
Received: 2016/06/25 | Accepted: 2016/06/25 | Published: 2016/06/25
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
